Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors,
Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH
Does the drug larotrectinib treat patients with solid tumors, non-Hodgkin lymphoma
or histiocytic disorders?
Basic Study Information
Purpose:Location: University of Rochester
This phase II Pediatric MATCH trial studies how well larotrectinib works in treating
with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions
spread to other places in the body and have come back or do not respond to treatment.
Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes
Lead Researcher (Principal Investigator)
Lead Researcher: Angela Girvin
Study Contact InformationPhone: (585) 275-5830
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search